\
&
Contact us
\
&
Contact us
Published on | 6 months ago
ProgrammesThe ERC is looking for ERC grantees to participate in the 2026 edition of the annual ‘Science is Wonderful!’ science fair. This event is aimed at primary and secondary school students and gives them the opportunity to interact with teams of researchers that showcase their work at booths through live experiments, interactive presentations, floor games, physical challenges and many other creative formats.
More information on the Science is wonderful! science fair 2026 edition, what is in it for ERC grantees and what is expected from them, the evaluation criteria and the timeline is available in the application form for ERC grantees which is open until 20 October 2025.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital Europe AI Continent Advanced Digital Skills Deployment: Best use of technologies
The European Commission has published a new round of calls under the Digital Europe programme. The submission period for the following call topics will open on 21 April 2026: Apply AI: Piloting AI-based image screening in medical centres Digital solutions for regulatory compliance through data Advanced Digital Skills for AI Uptake in Health... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
